Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance
Abstract Patients with ROS1-rearranged NSCLC demonstrate excellent disease control with ROS1-targeted therapy, but acquired resistance is inevitable. Of particular interest is the ROS1 L2086F kinase domain mutation which is refractory to all currently available ROS1 TKIs apart from cabozantinib. We...
Main Authors: | Mandy Sakamoto, Tejas Patil |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-06-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-023-00381-0 |
Similar Items
-
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
by: Jaime L. Schneider, et al.
Published: (2023-11-01) -
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
by: Elio Gregory Pizzutilo, MD, et al.
Published: (2023-11-01) -
Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
by: Parvin Begum, PhD, et al.
Published: (2022-09-01) -
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
by: Rohit Thummalapalli, MD, et al.
Published: (2023-08-01) -
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
by: Laura Fabbri, et al.
Published: (2023-12-01)